Citations

Clear

3485 citation(s) found for "Sy, Sarah".

The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans
Weiner, Michael W. , Aisen, Paul , Jack, Clifford R. , Jagust, William J. , Trojanowski, John Q. , Shaw, Leslie M. , Saykin, Andrew J. , Morris, John C. , Cairns, Nigel J. , Beckett, Laurel , Walter, Sarah , Soares, Holly , Snyder, Peter J. , Siemers, Eric , Potter, William Z., Cole, Patricia E., Initiative, Alzheimer's Disease Neuroimaging, Toga, Arthur W. , Green, Robert C. , Schmidt, Mark E. , Initiative, Alzheimer's Disease Neuroimaging, Jack, Clifford R , Saykin, Andrew J , Morris, John C

Mayo Clinic

Alzheimer's & Dementia | May 7, 2010 | Volume: 6 | Issue: 3 | Pages: 202

10.1016/j.jalz.2010.03.007 | PMID 20451868 Get It

The Alzheimer's Disease Neuroimaging Initiative (ADNI) beginning in October 2004, is a 6‐year research project that studies changes of cognition, function, brain structure and function, and biomarkers in elderly controls, subjects with mild cognitive impairment, and subjects with Alzheimer's disease (AD). A major goal is to determine and validate MRI, PET images, and cerebrospinal fluid (CSF)/blood biomarkers as predictors and outcomes for use in clinical trials of AD treatments. Structural MRI, FDG PET, C‐11 Pittsburgh compound B (PIB) PET, CSF measurements of amyloid β (Aβ) and species of tau, with clinical/cognitive measurements were performed on elderly controls, subjects with mild cognitive impairment, and subjects with AD. Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects. FDG PET, C‐11 Pittsburgh compound B PET, and CSF measurements of Aβ and tau were significant predictors of cognitive decline and brain atrophy. All data are available at UCLA/LONI/ADNI, without embargo. ADNI‐like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD.
Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans
Aisen, Paul , Petersen, Ronald C. , Donohue, Michael , Gamst, Anthony, Raman, Rema , Thomas, Ronald G. , Walter, Sarah , Trojanowski, John Q. , Shaw, Leslie M. , Beckett, Laurel , Jack, Clifford R. , Jagust, William J. , Toga, Arthur W. , Saykin, Andrew J. , Morris, John C. , Weiner, Michael W. , Initiative, Alzheimer's Disease Neuroimaging, Green, Robert C. , Initiative, Alzheimer's Disease Neuroimaging, Jack, Clifford R , Saykin, Andrew J , Toga, Arthur W , Morris, John C , Donohue, Michael C

Mayo Clinic

Alzheimer's & Dementia | May 7, 2010 | Volume: 6 | Issue: 3 | Pages: 239-246

10.1016/j.jalz.2010.03.006 | PMID 20451872 Get It

The Clinical Core of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has provided clinical, operational, and data management support to ADNI since its inception. This article reviews the activities and accomplishments of the core in support of ADNI aims. These include the enrollment and follow‐up of more than 800 subjects in the three original cohorts: healthy controls, amnestic mild cognitive impairment (now referred to as late MCI, or LMCI), and mild Alzheimer's disease (AD) in the first phase of ADNI (ADNI 1), with baseline longitudinal, clinical, and cognitive assessments. These data, when combined with genetic, neuroimaging, and cerebrospinal fluid measures, have provided important insights into the neurobiology of the AD spectrum. Furthermore, these data have facilitated the development of novel clinical trial designs. ADNI has recently been extended with funding from an NIH Grand Opportunities (GO) award, and the new ADNI GO phase has been launched; this includes the enrollment of a new cohort, called early MCI, with milder episodic memory impairment than the LMCI group. An application for a further 5 years of ADNI funding (ADNI 2) was recently submitted. This funding would support ongoing follow‐up of the original ADNI 1 and ADNI GO cohorts, as well as additional recruitment into all categories. The resulting data would provide valuable data on the earliest stages of AD, and support the development of interventions in these critically important populations.
Surgical Flow Disruptions: Measurement and Impact of Stressful Events in the Operating Room: Reply
Wiegmann, Douglas A. , Sundt, Thoralf M. , Parker, Sarah Henrickson

Mayo Clinic

World Journal of Surgery | April 8, 2010 | Volume: 34 | Issue: 9 | Pages: 2249-2250

10.1007/s00268-010-0555-8 Get It

Mutations in Fibrillin-1 Cause Congenital Scleroderma: Stiff Skin Syndrome
Loeys, Bart , Gerber, Elizabeth E. , Riegert‐Johnson, Douglas L. , Iqbal, Sarah , Whiteman, Pat, McConnell, Vivienne, Chillakuri, Chandramouli , Macaya, Daniela , Coucke, Paul , Paepe, Anne De , Judge, Daniel P. , Wigley, Fredrick M. , Mardon, Helen J., Handford, Penny A. , Keene, Douglas R. , Sakai, Lynn Y. , Dietz, Harry C. , Davis, Elise C. , Judge, Daniel P

Mayo Clinic

Science Translational Medicine | March 17, 2010 | Volume: 2 | Issue: 23 | Pages: No page available

10.1126/scitranslmed.3000488 | PMID 20375004 Get It

Stiff skin syndrome, an autosomal dominant congenital form of scleroderma, is caused by mutations in the domain of fibrillin-1 that mediates integrin binding.
Empowerment of Women and Its Association with the Health of the Community
Varkey, Prathibha, Kureshi, Sarah , Lesnick, Timothy G.

Mayo Clinic

Journal of Women's Health | January 20, 2010 | Volume: 19 | Issue: 1 | Pages: 71-76

10.1089/jwh.2009.1444 | PMID 20088661 Get It

Development and Evaluation of an Observational Tool for Assessing Surgical Flow Disruptions and Their Impact on Surgical Performance
Laviana, Aaron A. , Wadhera, Rishi K. , Wiegmann, Douglas A. , Sundt, Thoralf M. , Parker, Sarah , Wadhera, Rishi K

Mayo Clinic

World Journal of Surgery | December 9, 2009 | Volume: 34 | Issue: 2 | Pages: 353-361

10.1007/s00268-009-0312-z | PMID 20012288 Get It

AbstractBackgroundMany researchers have previously explored the correlation between surgical flow disruptions and adverse events in cardiac surgery; however, there is no reliable tool to prospectively categorize surgical flow disruptions and the conditions that predispose a surgical team to adverse events.MethodsTwo independent raters of different medical and human factors expertise observed 12 cardiovascular operations and iteratively designed a surgical flow disruption tool (SFDT) to characterize surgical flow disruptions and the latent factors that contribute to adverse events. Categories to characterize surgical flow disruptions were created based on human factors models of human error. After the design period, both raters observed ten surgical cases using the tool to assess validity and inter‐rater reliability.ResultsRating agreement (weighted kappa) for each category across the ten surgeries was moderate to very high, resulting in strong inter‐rater reliability for each category on the surgical flow disruption tool. Use of the SFDT was simple and clear for observers of diverse backgrounds, including human factors experts and medical personnel.ConclusionsThis research depicts the development and utility of a tool to analyze surgical flow disruptions in the cardiovascular operating room with satisfactory inter‐rater reliability. This tool is an important first step in systematically categorizing and measuring surgical flow disruptions and their impact on patient safety in the operating room.
Global Anesthesia Workforce Crisis: A Preliminary Survey Revealing Shortages Contributing to Undesirable Outcomes and Unsafe Practices
Dubowitz, Gerald, Detlefs, Sarah E. , McQueen, Kelly

Mayo Clinic

World Journal of Surgery | September 30, 2009 | Volume: 34 | Issue: 3 | Pages: 438-444

10.1007/s00268-009-0229-6 | PMID 19795163 Get It

AbstractBackgroundThe burden of disease, disability, and mortality that could be averted by surgery is growing. However, few low and middle income countries (LMICs) have the infrastructure or capacity to provide surgical services to meet this growing need. Equally, few of these countries have been assessed for key infrastructural capacity including surgical and anesthesia providers, equipment, and supplies. These assessments are critical to revealing magnitude of the evolving surgical and anesthesia workforce crisis, related morbidity and mortality, and necessary steps to mitigate the impact of the crisis.MethodsA pilot Internet‐based survey was conducted to estimate per‐capita anesthesia providers in LMICs. Information was obtained from e‐mail respondents at national health care addresses, and from individuals working in‐country on anesthesia‐related projects.ResultsWorkers from 6 of 98 countries responded to direct e‐mail inquiries, and an additional five responses came from individuals who were working or had worked in‐country at the time of the survey. The data collected revealed that the per‐capita anesthesia provider ratio in the countries surveyed was often 100 times lower than in developed countries.ConclusionsThis pilot study revealed that the number of anesthesia providers available per capita of population is markedly reduced in low and lower middle income countries compared to developed countries. As anesthesia providers are an integral part of the delivery of safe and effective surgical care, it is essential that more data is collected to fully understand the deficiencies in workforce and capacity in low and middle income countries.
Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803
Arndt, Carola A.S., Stoner, Julie A., Hawkins, Douglas S. , Rodeberg, David A. , Hayes‐Jordan, Andrea , Paidas, Charles N. , Parham, David M. , Teot, Lisa A., Wharam, Moody D., Breneman, John C. , Donaldson, Sarah S. , Anderson, James R. , Meyer, William H. , Hawkins, Douglas S , Donaldson, Sarah S

Mayo Clinic

Journal of Clinical Oncology | September 21, 2009 | Volume: 27 | Issue: 31 | Pages: 5182-5188

10.1200/jco.2009.22.3768 | PMID 19770373 Get It

Purpose The purpose of this study was to compare the outcome of patients with intermediate-risk rhabdomyosarcoma (RMS) treated with standard VAC (vincristine, dactinomycin, and cyclophosphamide) chemotherapy to that of patients treated with VAC alternating with vincristine, topotecan, and cyclophosphamide (VAC/VTC). Patients and Methods Patients were randomly assigned to 39 weeks of VAC versus VAC/VTC; local therapy began after week 12. Patients with parameningeal RMS with intracranial extension (PME) were treated with VAC and immediate x-ray therapy. The primary study end point was failure-free survival (FFS). The study was designed with 80% power (5% two-sided α level) to detect an increase in 5-year FFS from 64% to 75% with VAC/VTC. Results A total of 617 eligible patients were entered onto the study: 264 were randomly assigned to VAC and 252 to VAC/VTC; 101 PME patients were nonrandomly treated with VAC. Treatment strata were embryonal RMS, stage 2/3, group III (33%); embryonal RMS, group IV, less than age 10 years (7%); alveolar RMS or undifferentiated sarcoma (UDS), stage 1 or group I (17%); alveolar RMS/UDS (27%); and PME (16%). At a median follow-up of 4.3 years, 4-year FFS was 73% with VAC and 68% with VAC/VTC (P = .3). There was no difference in effect of VAC versus VAC/VTC across risk groups. The frequency of second malignancies was similar between the two treatment groups. Conclusion For intermediate-risk RMS, VAC/VTC does not significantly improve FFS compared with VAC.
Strategies for Avoiding Burnout in Hospice and Palliative Medicine: Peer Advice for Physicians on Achieving Longevity and Fulfillment
Swetz, Keith M. , Harrington, Sarah , Matsuyama, Robin K. , Lyckholm, Laurie , Shanafelt, Tait D.

Mayo Clinic

Journal of Palliative Medicine | July 21, 2009 | Volume: 12 | Issue: 9 | Pages: 773-777

10.1089/jpm.2009.0050 | PMID 19622012 Get It

Vision screening for amblyopia in childhood
Powell, Christine, Hatt, Sarah R.

Mayo Clinic

Cochrane Database of Systematic Reviews | July 3, 2009 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/14651858.cd005020.pub3 | PMID 19588363 Get It